title: In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors.
abstract: The in vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development have been investigated in transgenic (Tg) mice (IGF-II/I Tg mice) in whom an IGF-II promoter-driven IGF-I transgene is highly expressed in cerebellum. Compared to normal littermates, the brains of IGF-II/I Tg mice exhibited overgrowth beginning from the second week of postnatal life. Among the brain regions examined, cerebellum exhibited the greatest increase in size, such that by 50 days of age cerebellar weight and DNA content were increased by 90% and 143%, respectively, compared to littermate controls. Morphological studies of adult IGF-II/I Tg mice showed that the total number of granule and Purkinje cells was increased by 82% and 20%, respectively, findings consistent with the increased cerebellar DNA content and indicating that the increased cerebellar weight was due in part to an increase in cell number. The thickness of the molecular layer also was increased in IGF-II/I Tg mice. During early postnatal development the number of external granular layer cells, as well as the number of BrdU labeled external granular cells, was increased. These data strongly indicate that IGF-I increases granule cell number by a mechanism that involves the stimulation of granule cell progenitor proliferation. Our findings also indicate that IGF-I influences the growth of Purkinje cells and possibly of other cell types in the cerebellum.
authors.affiliation: Department of Pediatrics, University of North Carolina at Chapel Hill 27599-7220, USA.
authors.forename: P
authors.initials: P
authors.lastname: Ye
authors.forename: Y
authors.initials: Y
authors.lastname: Xing
authors.forename: Z
authors.initials: Z
authors.lastname: Dai
authors.forename: A J
authors.initials: AJ
authors.lastname: D'Ercole
mesh_terms: D000818:Animals; D000963:Antimetabolites; D015152:Blotting, Northern; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D001973:Bromodeoxyuridine; D002455:Cell Division / Q000502:physiology; D002531:Cerebellum / Q000166:cytology* / Q000254:growth & development* / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis; D015342:DNA Probes; D005786:Gene Expression Regulation / Q000502:physiology; D017403:In Situ Hybridization; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis / Q000502:physiology*; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D009929:Organ Size / Q000187:drug effects / Q000502:physiology; D011689:Purkinje Cells / Q000378:metabolism / Q000502:physiology; D012333:RNA, Messenger / Q000096:biosynthesis; D013234:Stem Cells / Q000502:physiology*; D019076:Transgenes
chemical_list: D000963:Antimetabolites; D015342:DNA Probes; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D004247:DNA; D001973:Bromodeoxyuridine